Written question asked by Jess Brown-Fuller (Liberal Democrat) on Thursday, 17 April 2025, in the House of Commons. It was due for an answer on Wednesday, 23 April 2025. It was answered by Karin Smyth (Labour) on Tuesday, 29 April 2025 on behalf of the Department of Health and Social Care.

Methylphenidate and Pancreatic Enzyme Replacement Therapy: Import Duties

Question: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of US tariffs on the domestic supply of (a) methylphenidate and (b) pancreatic enzyme replacement therapy.

Answer: The Department is working closely with life sciences stakeholders and other Government departments to assess the potential impact of United States tariffs on global medicine supply chains. We have a range of well-established processes to mitigate risks to patients where there are shortages. We will continue to review the need to utilise these procedures as more information becomes available on the impact of tariffs on any specific products or companies.

Secondary information

Type: Written question
Reference: 46602
Session: 2024-26
Subjects: Import duties USA Methylphenidate Pancreatic enzyme replacement therapy
Link: View this Written question on www.parliament.uk